IceCure Medical (ICCM) Cash & Equivalents (2020 - 2026)

IceCure Medical (ICCM) has 7 years of Cash & Equivalents data on file, last reported at $8.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 34.35% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $8.1 million, a 34.35% increase from a year earlier, with the FY2025 full-year figure at $8.9 million, up 17.62% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $8.1 million, down from $8.9 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ICCM reached as high as $39.0 billion in Q4 2024 and fell as low as $3.0 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $2.3 billion across 5 years, with a median of $9.7 million in 2024.
• Across the five-year window, Cash & Equivalents surged 370164.88% in 2024 and tumbled 99.98% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $23.7 million in 2022, then plunged by 55.48% to $10.5 million in 2023, then jumped by 370164.88% to $39.0 billion in 2024, then tumbled by 99.98% to $8.9 million in 2025, then dropped by 8.79% to $8.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $8.1 million in Q1 2026, $8.9 million in Q4 2025, and $5.0 million in Q3 2025.